“…Clofibrate (ethyl p-chlorophenoxyisobutyrate) has been studied and used extensively (3)(4)(5), but less is known about the biochemical and physiological effects of various other hypolipidemic agents such as tibric acid [2-chloro-5-(cis-3,5-dimethylpiperidinosulfonyl)benzoicacid] (4,6-8), SaH-42-348f1-methyl-4-piperidyl bis-(p-chlorophenoxy)acetate] (9, 10), S-321328 [(4R)-4-(2,3,4,6,6ap,7,8,9,9aa,9b,-decahydro-6a/3-methyl- '3 -oxo-lH-cyclopenta[f]-quinolin-7,B3yl)valeric acid (11), WY-14643 ([4-chloro-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) (4,(12)(13)(14), S-8527 (1,1-bis-[4'-(1"-carboxy-1"-methylpropoxy)phenyl]cyclohexane) (15)(16)(17)(18)(19), and DH-990 (2-[3,5-di-(t-butyl-4-hydroxyphenyl)thio]hexanoic acid) (4). The effectiveness of these agents generally has been attributed to their ability to interfere with certain phases of fatty acid (15,18,(20)(21)(22)(23), triglyceride (8,(23)(24)(25)(26)(27)(28)(29)(30)(31), and cholesterol (11,14,15,(32)(33)(34)(35)(36)(37)…”